⌕
ArriVent BioPharma · AVBP · Nasdaq
Tenet 69 · Solid
Compare
$10.69−7.53%At closeTenet 69 · Solid
$10.69−0.87 (−7.53%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

ArriVent BioPharma (AVBP) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is AVBP's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 15, 2026 · 05:18 ET
ArriVent BioPharma: ARR-217 Gives Us A Reason To Reconsider Our Strong Sell (Rating Upgrade)

Following firmonertinib's Phase 3 failure, we downgraded ArriVent BioPharma to Strong Sell. Shares have since declined another 14%. ARR-217 showed a 44.8% response rate in early colorectal cancer data, although only seve…

AVBP −7.5% todayRead at source ↗
● GlobeNewsWireNov 9, 2026 · 16:01 ETCOMPANY'S OWN WORDS
ArriVent BioPharma Reports Third Quarter 2026 Financial Results

Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO Dosed first patient in U.S. P…

AVBP −7.5% todayRead at source ↗
● Business WireNov 2, 2026 · 17:00 ET
Aarvik Therapeutics Announces Milestone Achievement, Partnership Update, and Presentations on MUTTA™ and AQUALINK™ Platforms at the 17th Annual WADC Conference

HAYWARD, Calif.--(BUSINESS WIRE)-- #biotechnology--Aarvik Therapeutics (Aarvik), an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce im…

AVBP −7.5% todayRead at source ↗
● Newsfile CorpOct 28, 2026 · 10:00 ET
Arrivent Biopharma Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your AVBP Investments

New York, New York--(Newsfile Corp. - October 28, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of Arrivent BioPharma ("Arrivent" or the "Company") (NASDAQ: AVBP) investors concerning …

AVBP −7.5% todayRead at source ↗
● MarketBeatOct 27, 2026 · 00:02 ET
ArriVent BioPharma's ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study

ArriVent BioPharma NASDAQ: AVBP presented Phase I data for ARR-217, its CDH17-targeting antibody-drug conjugate, or ADC, in heavily pretreated metastatic colorectal cancer patients during a virtual webinar following an E…

AVBP −7.5% todayRead at source ↗
● GlobeNewsWireOct 25, 2026 · 09:00 ETCOMPANY'S OWN WORDS
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026

NEWTOWN SQUARE, Pa., Oct. 25, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceuti…

AVBP −7.5% todayRead at source ↗
● GlobeNewsWireOct 23, 2026 · 16:00 ETCOMPANY'S OWN WORDS
ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026

NEWTOWN SQUARE, Pa., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceuti…

AVBP −7.5% todayRead at source ↗
● Business WireOct 21, 2026 · 18:00 ET
ARRIVENT BIOPHARMA AVBP INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 47.3% Share Drop

NEW YORK--(BUSINESS WIRE)---- $AVBP #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Arrivent BioPharma (“Arrivent” or the “Company”) (NASDAQ: AVBP) investors c…

AVBP −7.5% todayRead at source ↗
● GlobeNewsWireOct 19, 2026 · 08:01 ETCOMPANY'S OWN WORDS
ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer

NEWTOWN SQUARE, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceuti…

AVBP −7.5% todayRead at source ↗
● GlobeNewsWireOct 13, 2026 · 15:42 ET
ARRIVENT BIOPHARMA INVESTIGATION: AVBP Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Arrivent BioPharma (“Arrivent” or the “Company”) (NASDAQ: AVBP). The investigation concerns whethe…

AVBP −7.5% todayRead at source ↗
● PRNewsWireOct 13, 2026 · 15:10 ETCOMPANY'S OWN WORDS
ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky

ArriVent BioPharma shares lost more than half their value after the pivotal Phase 3 FURVENT trial of lead candidate firmonertinib missed its primary endpoint. An investigation into potential securities law violations is …

AVBP −7.5% todayRead at source ↗
● GlobeNewsWireOct 12, 2026 · 16:01 ETCOMPANY'S OWN WORDS
ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002

NEWTOWN SQUARE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceuti…

AVBP −7.5% todayRead at source ↗
● GuruFocusOct 7, 2026 · 23:00 ET
AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law

[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv…

AVBP −7.5% todayRead at source ↗
● PRNewsWireOct 7, 2026 · 14:20 ET
AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma

AVBP was down 56.7% before the opening bell and traded as low as $12.09 after ArriVent disclosed that its Phase 3 FURVENT trial of firmonertinib missed its primary endpoint. An investigation into potential securities law…

AVBP −7.5% todayRead at source ↗
● PRNewsWireOct 6, 2026 · 17:47 ET
ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)

AVBP shareholders are holding stock near a $12.09 52-week low after the Phase 3 FURVENT trial missed its primary endpoint, just five months after ArriVent launched a $250 million at-the-market stock offering. NEW YORK, O…

AVBP −7.5% todayRead at source ↗
● BenzingaOct 6, 2026 · 14:09 ET
ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low

ArriVent BioPharma Inc. (NASDAQ:AVBP) stock fell on Tuesday with a session volume of 14.10 million compared to the average volume of 524.163 thousand, according to Benzinga Pro data.…

AVBP −7.5% todayRead at source ↗
● Defense WorldOct 6, 2026 · 10:00 ET
ArriVent BioPharma (NASDAQ:AVBP) Reaches New 12-Month Low – What’s Next?

ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) reached a new 52-week low during trading on Tuesday. The company traded as low as $11.66 and last traded at $12.00, with a volume of 1687237 shares traded. The st…

AVBP −7.5% todayRead at source ↗
● GlobeNewsWireOct 6, 2026 · 08:00 ET
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC

NEWTOWN SQUARE, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceuti…

AVBP −7.5% todayRead at source ↗
● Defense WorldSep 21, 2026 · 02:15 ET
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Rating of “Moderate Buy” from Analysts

ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst ha…

AVBP −7.5% todayRead at source ↗
● Defense WorldAug 30, 2026 · 04:14 ET
Deutsche Bank AG Acquires Shares of 39,180 ArriVent BioPharma, Inc. $AVBP

Deutsche Bank AG bought a new position in shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP) in a recent quarter, according to its most recent disclosure with the SEC. The institutional investor bought 39,180 shares of th…

AVBP −7.5% todayRead at source ↗
● Seeking AlphaAug 27, 2026 · 04:00 ET
ArriVent BioPharma: Firmonertinib Delay Strengthens The Upside Case

The Firmonertinib readout moving to H2 2026 may signal slower event accumulation and longer progression-free survival. Firmonertinib remains the core value driver, with our base case assuming meaningful penetration acros…

AVBP −7.5% todayRead at source ↗
● Defense WorldAug 27, 2026 · 02:16 ET
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the ten analysts that are presently covering the stock, Marketbeat reports. One equ…

AVBP −7.5% todayRead at source ↗

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just AVBP · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.